NVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Novo Nordisk A/S's research and development for the three months ended in Mar. 2016 was $493 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2016 was $2,034 Mil.
This is the expense the company spent on research and development.
Novo Nordisk A/S Research & Development for the trailing twelve months (TTM) ended in Mar. 2016 was 456.665663557 (Jun. 2015 ) + 494.980962271 (Sep. 2015 ) + 588.647307748 (Dec. 2015 ) + 493.237392888 (Mar. 2016 ) = $2,034 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Novo Nordisk A/S Annual Data
|Research & Development||1,119||1,669||1,425||1,540||1,703||1,703||1,916||2,156||2,280||1,986|
Novo Nordisk A/S Quarterly Data
|Research & Development||655||587||561||633||640||471||457||495||589||493|